Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Open Orphan Plc ( (GB:HVO) ) has issued an update.
hVIVO plc has disclosed that non-executive director Brendan Buckley sold 2,017,000 ordinary shares in the company at 8.65p per share, reducing his holding to 2,000,270 shares. Buckley has also informed the company that he does not intend to stand for re-election at the upcoming annual general meeting, signalling a planned change in the board’s composition.
The transaction, conducted on 24 April 2026 on AIM, has been classified as inside information under the Market Abuse Regulation and is now in the public domain following this disclosure. While the sale represents a significant disposal by a board member, the company has not indicated any direct operational impact, though investors may view the move and Buckley’s impending departure as noteworthy for governance and sentiment around the stock.
The most recent analyst rating on (GB:HVO) stock is a Buy with a £10.00 price target. To see the full list of analyst forecasts on Open Orphan Plc stock, see the GB:HVO Stock Forecast page.
Spark’s Take on HVO Stock
According to Spark, TipRanks’ AI Analyst, HVO is a Neutral.
The score is held back primarily by the latest financial deterioration (losses, negative gross profit, and significant cash flow weakness). Offsetting this are moderately positive technical momentum signals and earnings-call indications of improving demand/pipeline, though liquidity and booking visibility remain key near-term risks.
To see Spark’s full report on HVO stock, click here.
More about Open Orphan Plc
hVIVO plc is a purpose-built, full-service international clinical development partner and the global leader in human challenge trials, working with seven of the world’s ten largest biopharma companies. The group offers an end-to-end platform from preclinical strategy through first-in-human and Phase II trials to specialist laboratory services, supported by a large participant database and facilities in the UK and Germany.
Average Trading Volume: 3,918,241
Technical Sentiment Signal: Sell
Current Market Cap: £52.32M
For an in-depth examination of HVO stock, go to TipRanks’ Overview page.